This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GVH | |
|---|---|
| Name | GVH |
| Specialty | Hematology; Transplantation |
GVH is a post-transplant immunologic syndrome arising after allogeneic hematopoietic cell transfer and related graft procedures. It results from donor-derived immune cells recognizing recipient tissues as antigenically foreign, producing a spectrum of acute and chronic manifestations involving skin, liver, mucosae, and gastrointestinal tract. Clinical management intersects transplantation medicine, immunology, and supportive care, and long-term outcomes depend on donor selection, conditioning regimens, and prophylactic strategies.
GVH denotes a condition in which transplanted immunocompetent cells cause host tissue injury; terminology distinguishes acute from chronic forms based on timing and pathologic features. Canonical nomenclature in transplantation literature contrasts acute presentations occurring within the early post-engraftment period with chronic syndromes that may follow or occur de novo, and consensus criteria developed by major transplant consortia guide staging and grading. Related terms appear throughout reports from institutions such as National Institutes of Health, European Society for Blood and Marrow Transplantation, American Society of Hematology, British Society for Haematology, and in guidelines from regulatory bodies like Food and Drug Administration and European Medicines Agency.
The initiating event is donor lymphocyte recognition of recipient alloantigens presented by host antigen-presenting cells, leading to donor T cell activation, expansion, and effector function. Key molecular mediators identified in mechanistic studies include donor CD4+ and CD8+ subsets, cytokines such as interleukin-2 and tumor necrosis factor-alpha, and pathways involving costimulatory molecules described in reports from Johns Hopkins Hospital, Mayo Clinic, and Fred Hutchinson Cancer Center. Host factors such as HLA mismatch, minor histocompatibility antigens, conditioning intensity, and recipient antigen-presenting cell chimerism influence risk; seminal work from groups at Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Stanford University elucidated contributions of regulatory T cells and thymic function. Animal models from National Institutes of Health intramural programs and classic murine studies mapped phases of activation, amplification, and target tissue injury implicating innate sensors and microbiome interactions described in collaborations with teams at Massachusetts General Hospital and University of California, San Francisco.
Acute presentations typically include skin eruptions, hepatic dysfunction with bilirubin elevation, and gastrointestinal symptoms such as secretory diarrhea and abdominal pain; biopsy findings reveal interface dermatitis, bile duct damage, or crypt apoptosis respectively. Chronic presentations can mimic autoimmune syndromes with sclerodermoid skin changes, bronchiolitis obliterans, and ocular sicca, and diagnostic criteria integrate clinical staging, histopathology, and objective testing such as pulmonary function testing used by centers including Cleveland Clinic, University of Pennsylvania, and Columbia University Irving Medical Center. Diagnostic algorithms reference laboratory studies including complete blood counts, liver function panels, and infectious workups, and leverage imaging modalities employed at Memorial Sloan Kettering Cancer Center and pathology assessments standardized by pathology groups at Mayo Clinic and University of Michigan Health.
Management centers on immunosuppressive strategies to control donor T cell–mediated injury while preserving graft-versus-tumor effects; first-line therapy frequently involves corticosteroids, calcineurin inhibitors such as tacrolimus or cyclosporine, and adjunctive agents. Second-line and steroid-refractory approaches incorporate monoclonal antibodies and cellular therapies informed by trials at Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center, Stanford University, and pharmaceutical-sponsored studies reviewed by European Medicines Agency. Supportive measures include skin care regimens developed in dermatology collaborations at Cleveland Clinic and Johns Hopkins Hospital, nutritional support guided by dietitians at Mayo Clinic, and infectious prophylaxis protocols from Centers for Disease Control and Prevention and transplant consortia. Emerging therapies target cytokine signaling, costimulation blockade, and regulatory T cell augmentation investigated at institutions such as University of Cambridge, University of Oxford, and Karolinska Institutet.
Prognosis varies with severity, organ involvement, and response to therapy; severe acute presentations confer substantial morbidity and mortality described in multicenter outcome studies from Seattle Cancer Care Alliance and registries maintained by Center for International Blood and Marrow Transplant Research. Chronic forms contribute to long-term disability including cutaneous fibrosis, pulmonary compromise, ocular morbidity, and secondary infections; late effects have been characterized in survivorship cohorts at St. Jude Children’s Research Hospital and Children’s Hospital of Philadelphia for pediatric populations. Complications include opportunistic infections, metabolic sequelae of prolonged immunosuppression, and relapse risk modulation documented in longitudinal analyses from MD Anderson Cancer Center and European transplant registries.
Incidence and prevalence depend on transplant population, donor type, conditioning regimen, and prophylactic strategies; epidemiologic data are reported by registries such as Center for International Blood and Marrow Transplant Research, European Society for Blood and Marrow Transplantation, and national transplant databases in Japan, South Korea, and countries participating in multicenter consortia. Prevention emphasizes donor selection, HLA matching, graft manipulation (e.g., T cell depletion), and pharmacologic prophylaxis including calcineurin inhibitors and post-transplant cyclophosphamide, with landmark clinical trials from Johns Hopkins Hospital and Dana-Farber Cancer Institute informing contemporary practice. Public health and policy implications are addressed in consensus statements from World Health Organization and professional societies guiding screening, registries, and research priorities.
Category:Transplantation-related disorders